Minneapolis-based Vensana Capital, a new venture firm partnering with medical technology companies, launched Sept. 4 with the close of its oversubscribed inaugural fund, Vensana Capital I.
The fund raised $225 million from investors including academic health systems, university endowments, foundations and family offices, among other institutional investors. Vensana will use the fund to invest in companies in the clinical development and commercialization stages, with a focus on those developing medical devices, diagnostics and data science, drug delivery, digital health and tech-enabled services.
Vensana was co-founded by managing partners Kirk Nielsen and Justin Klein, MD, who, along with the rest of the Vensana staff, have a history of investing in innovative medtech companies such as CardiAQ, Cartiva, CV Ingenuity and more.
More articles on innovation:
America's Most Innovative Leaders: 24 healthcare leaders on the list
3 strategies that slow, rather than speed, innovation
7 key quotes about hospital innovation